An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma
This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : arsenic trioxide
- other : laboratory biomarker analysis
Ages Eligible For Study:
- Patients with basal cell carcinoma (BCC) - Patients ineligible for curative locoregional treatment and have either progressed on, did not tolerate, unwilling to try or ineligible for investigational smoothened antagonist such as vismodegib (GDC 0449), XL 139 (BMS 833923), IPI- 926, LDE225 and PF-04449913 - Life expectancy estimate > 3 months - Performance status Eastern Cooperative Oncology Group (ECOG) 0-2 - Absolute neutrophil count >= 1,500/mcL - Platelets >= 100,000/mcL - Total bilirubin within normal institutional limits - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal - Creatinine within normal institutional limits - Corrected QT interval (QTC) by 12 lead electrocardiogram (EKG) < 450 msecs - Serum potassium within normal limits - Magnesium within normal limits - Calcium within normal limits - Include the following: ability to understand and the willingness to sign a written informed consent document - Patients must have evaluable tumor and be potentially eligible for pre and post ATO tumor biopsy